Mor Frisch¹, Noa Zur Aviran¹, Elena Didkovsky^2,3, Daniel Mimouni^1,2, Yael A Leshem^1,2, Omri Zidan¹ and Lihi Atzmony⁴*

¹ Division of Dermatology, Rabin Medical Center, Petach Tikva, Israel
²Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
³Department of Pathology and Cytology, Rabin Medical Center, Petach Tikva, Israel
⁴Department of Dermatology, Yale School of Medicine, New Haven, CT, USA

*Corresponding Author: Lihi Atzmony, Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.

Received: April 14, 2025; Published: April 25, 2025

Abstract

Background: Keloidal Morphea represents a rare and challenging variant within the spectrum of morphea and systemic sclerosis, characterized by keloid-like or hypertrophic scar like-nodules

Objective: We sought to assess the current evidence regarding keloidal morphea.

Methods: We conducted a systematic review of the literature available on PubMed, supplemented with four additional cases from Rabin Medical Center

Results: Our initial search yielded 812 results of whom, 52 reports met the inclusion criteria leading to a total of 69 cases. Keloidal morphea predominantly affects females (87%) and is most prevalent among individuals aged 30-50, with a notable prevalence in African Americans, highlighting a potential genetic predisposition to keloid formation in darker skin types. Keloidal morphea can oc cur alone or alongside systemic sclerosis, observed in 58% of the cases. The trunk and upper limbs are the most frequently involved areas. Both isolated and systemic sclerosis-associated keloidal morphea exhibit similar clinical and histological features, which sug gests shared pathophysiological aspects. The complexity of these manifestations makes management challenging, with treatments ranging from steroids to phototherapy, yet often resulting in only modest improvements.

Limitations: Low quality of evidence, variability in the extent of data, lack of studies.

Conclusion: The presence of keloidal morphea in both isolated and systemic sclerosis contexts underscores the need for further research into its pathophysiology and treatment. This review aims to enhance understanding and guide future research efforts to improve the outcomes for keloidal morphea patients, emphasizing the importance of recognizing this condition in patients with sys temic sclerosis and in populations with a predisposition to keloid development.

Keywords: Morphea; Keloid; Systemic Sclerosis; Scleroderma

References

1. Sobolewski P., et al. “Systemic sclerosis - multidisciplinary disease: clinical features and treatment”. Reumatologia4 (2019): 221-233.
2. Bolognia JL., et al. “Dermatology”. 4^th, (2018): 693-721.
3. Fett NM. “Morphea (localized scleroderma)”. JAMA Dermatology9 (2013): 1124.
4. Sartori-Valinotti JC., et al. “Updates on morphea: role of vascular injury and advances in treatment”. Autoimmune Disease 2013 (2019): 467808.
5. Mayes MD. “Classification and epidemiology of scleroderma”. Seminars in Cutaneous Medicine and Surgery 1 (1998): 22-26.
6. Addison T. “On the Keloid of Alibert, and on True Keloid”. Medico Chirurgical Transactions 37 (1854): 27-47.
7. Unna P. “Die histopathologie der hautkrankheiten”. edn. berlin, hirchwald, (1894): 1119.
8. Rencic A., et al. “Keloid morphea and nodular scleroderma: two distinct clinical variants of scleroderma?” Journal of Cutaneous Medicine and Surgery1 (2003): 20-24.
9. Ling TC., et al. “Keloidal scleroderma”. Clinical and Experimental Dermatology2 (2003): 171-173.
10. Yu D., et al. “Morphea With Keloidal Features: A Case Report and Review of the Literature”. American Journal of Dermatopathology10 (2020): 766-768.
11. Richarz NA., et al. “A review of the clinically distinguishing features of nodular or keloidal scleroderma in systemic sclerosis”. Australas Journal of Dermatology2 (2020): e269-e273.
12. Ohata C., et al. “Nodular morphea (NM report of a case of concurrent NM and morphea profunda associated with limited type systemic sclerosis, and overview and definition for NM”. European Journal of Dermatology1 (2013): 87-93.
13. Cannick L., et al. “Nodular scleroderma: case report and literature review”. Journal of Rheumatology11 (2003): 2500-2502.
14. Kassira S., et al. “Keloidal Scleroderma: Case Report and Review”. Case Reports in Dermatological Medicine 2015 (2015): 635481.
15. Toki S., et al. “Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma”. Journal of Dermatology3 (2015): 283-287.
16. Soma Y., et al. “Coexistence of morphea and systemic sclerosis”. Dermatology2 (1993): 103-105.
17. Alster TS and Tanzi EL. “Hypertrophic scars and keloids: etiology and management”. American Journal of Clinical Dermatology4 (2003): 235-243.
18. English RS and Shenefelt PD. “Keloids and hypertrophic scars”. Dermatology Surgery8 (1999): 631-638.
19. Knowles A., et al. “Keloids and Hypertrophic Scars”. Dermatology Clinics3 (2023): 509-517.
20. Mayes MD., et al. “Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population”. Arthritis Rheumatology8 (2003): 2246-2255.
21. Barzilai A., et al. “Keloid-like scleroderma”. American Journal of Dermatopathology4 (2003): 327-330.
22. Li Y., et al. “Nodular and diffuse spindle cell infiltration in keloidal scleroderma: a case report”. Frontiers in Medicine (Lausanne) 10 (2023): 1291941.
23. Marcelus C., et al. “Questions raised by a case of adult-onset linear nodular scleroderma”. Dermatology Online Journal 5 (2022).
24. Castelli E., et al. “Nodular morphea keloidal type: A rare case with paradigmatic histopathology significantly accompanied by a flawless surgical scar”. Journal of Cutaneous Pathology 11 (2021): 1329-1334.
25. Hammami F., et al. “Atypical Keloidal Morphea”. Skinmed 2 (2021): 132-133.
26. Dadkhahfar S., et al. “Development of keloidal morphea after treatment with cyclosporine in a case of recalcitrant generalized morphea”. Clinical Case Report5 (2020): 837-839.
27. Campione E., et al. “Nodular morphea in a patient with Steinert disease”. Italian Journal of Dermatology and Venereology 2 (2019): 209-210.
28. Nakazato S., et al. “Nodular morphoea: a first case associated with linear morphoea”. European Journal of Dermatology1 (2016): 95-96.
29. Torchia D and Schachner LA. “Superimposed segmental morphea with keloidal features”. International Journal of Dermatology8 (2015): 944-945.
30. Salmon NE., et al. “Keloid-like morphoea”. Clinical and Experimental Dermatology1 (2014): 90-91.
31. El Khoury J., et al. “Indurated hyperpigmented plaques with overlying fibrotic nodules in an adolescent boy”. Pediatrics Dermatology1 (2012): 111-112.
32. Chiu HY and Tsai TF. “Images in clinical medicine. Keloidal morphea”. The New England Journal of Medicine 1 (2011): 4 e28.
33. Kauer F., et al. “Nodular morphea”. Dermatology1 (2009): 63-66.
34. Jain K., et al. “Blaschko linear nodular morphea with dermal mucinosis”. Archives of Dermatology7 (2007): 953-955.
35. Yoshinaga E., et al. “Acrokeratoelastoidosis associated with nodular scleroderma”. European Journal of Dermatology5 (2003): 490-492.
36. Labandeira J., et al. “Polymorphic fibrosing reaction mimicking keloidal scleroderma but without associated classic scleroderma”. Dermatology2 (2003): 204-205.
37. Hsu S., et al. “Nodular morphea in a linear pattern”. International Journal of Dermatology 7 (1999): 529-530.
38. Kubo M., et al. “Keloidlike morphea”. Acta Dermato-Venereologica1 (1997): 90-91.
39. Micalizzi C., et al. “Morphoea with nodular lesions”. British Journal of Dermatology2 (1994): 298-300.
40. BETTLEY FR. “Progressive symmetrical sclerodermia with sclerodermatous nodules”. Proceedings of the Royal Society of Medicine 7 (1951): 573-575.
41. Kuzumi A., et al. “Extensive keloidal morphea in a patient with systemic sclerosis”. American Journal of Medical Sciences 5 (2024): e58-e59.
42. Sanchez NG., et al. “Nodular (keloidal) scleroderma”. Rheumatology Clinics (Engl Ed) 8 (2023): 463-464.
43. Chattopadhyay A., et al. “Keloidal Morphea: Clinical Picture”. Journal of Clinical Rheumatology6 (2020): e178-e179.
44. Srisuttiyakorn C and Aunhachoke K. “Scleroderma with Nodular Scleroderma”. Case Reports on Dermatology3 (2016): 303-310.
45. Lortscher DN., et al. “Nodular Scleroderma Revisited: Systemic Sclerosis Presenting as Annular Keloidal Sclerotic Plaques”. Journal Of Clinical And Aesthetic Dermatology 6 (2016): 56-57.
46. Spierings J., et al. “Nodular Scleroderma”. Arthritis Rheumatology12 (2015): 3157.
47. Kokpol C., et al. “Nodular scleroderma in a patient with chronic hepatitis C virus infection: a coexistent or causal infection?” Cutis 2 (2015): E19-22.
48. Stadler B., et al. “Systemic sclerosis with keloidal nodules”. Anais Brasileiros de Dermatologia6 (2013): 75-77.
49. Moinzadeh P., et al. “Systemic sclerosis with multiple nodules: characterization of the extracellular matrix”. Archives of Dermatology7 (2013): 645-652.
50. Sen S., et al. “Keloids in scleroderma-keloidal scleroderma: a unique entity. Indian Journal of Dermatology2 (2013): 153-154.
51. Heath CR., et al. “Nodular scleroderma presenting as multiple spontaneous keloidal scars”. Journal of the American Academy of Dermatology6 (2012) e245-246.
52. Le EN., et al. “Nodular/keloidal scleroderma: acquired collagenous nodules in systemic sclerosis”. Journal of Rheumatology3 (2012): 660-661.
53. Wriston CC., et al. “Nodular scleroderma: a report of 2 cases”. American Journal of Dermatopathology4 (2008): 385-388.
54. Melani L., et al. “A case of nodular scleroderma”. Journal of Dermatology12 (2005): 1028-1031.
55. Yamamoto T., et al. “Nodular scleroderma: increased expression of connective tissue growth factor”. Dermatology3 (2005): 218-223.
56. Santiago M., et al. “Keloidal scleroderma”. Clinical Rheumatology1 (2004): 50-51.
57. Mizutani H., et al. “Nodular scleroderma: focally increased tenascin expression differing from that in the surrounding scleroderma skin”. Journal of Dermatology4 (1995): 267-271.
58. Krell JM., et al. “Nodular scleroderma”. Journal of the American Academy of Dermatology2 (1995): 343-345.
59. Yamamoto T., et al. “Nodular scleroderma in a worker using a silica-containing abrasive”. Journal of Dermatology10 (1994): 751-754.
60. Sasaki T., et al. “Nodular scleroderma in systemic sclerosis under D-penicillamine therapy”. Journal of Dermatology 12 (1992): 968-971.
61. Perez-Wilson J., et al. “Nodular (keloidal) scleroderma”. International Journal of Dermatology6 (1992): 422-423.
62. Akintewe TA and Alabi GO. “Scleroderma presenting with multiple keloids”. British Medical Journal (Clin Res Ed).6493 (1985): 448-449.
63. James WD., et al. “Nodular (keloidal) scleroderma”. Journal of the American Academy of Dermatology6 (1984): 1111-1114.
64. Cantwell AR Jr., et al. “Nodular scleroderma and pleomorphic acid-fast bacteria”. Archives of Dermatology11 (1980): 1283-1290.
65. Kennedy C and Leigh IM. “Systemic sclerosis with subcutaneous nodules”. British Journal of Dermatology1 (1979): 93-96.

Citation

Citation: Lihi Atzmony., et al. “Keloidal Morphea: A Systematic Review of The Literature". Acta Scientific Paediatrics 8.5 (2025): 14-37.

Copyright

Copyright: © 2025 Lihi Atzmony., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.